🧬 ctDNA Testing Cancer Research

Circulating tumor DNA (ctDNA) testing represents a promising advancement in cancer detection and monitoring. This innovative blood test analyzes fragments of DNA shed by cancer cells into the bloodstream, potentially allowing doctors to detect cancer earlier and track treatment response more accurately than traditional methods. ctDNA testing belongs to the growing field of liquid biopsy diagnostics, which offers several advantages including non-invasiveness, ease of repeated sampling, and the ability to detect cancer-related genetic changes with high sensitivity.

Researchers worldwide are actively studying how ctDNA testing can improve cancer care across multiple cancer types. Current research explores ctDNA's potential for early cancer detection in asymptomatic individuals, monitoring minimal residual disease after treatment, predicting treatment response, and identifying cancer recurrence before symptoms appear. The technology continues to evolve rapidly, with studies examining optimal detection methods, clinical utility in different patient populations, and integration into standard cancer care pathways.

This page features the latest peer-reviewed research on ctDNA testing and biomarker analysis in cancer diagnostics. Whether you're a patient seeking to understand this technology, a caregiver supporting a loved one, or someone interested in cancer research advances, the articles below represent current scientific findings from leading cancer research institutions and clinical trials worldwide.